- Cano Health Inc CANO has announced Q2 revenue of $393.2 million, +130% Y/Y, compared to $171.20 million a year ago, driven by acquisitions and membership growth.
- The total membership of 156,038, including Medicare capitated members, reached 111,866, +57% and 54%, respectively.
- Adjusted EBITDA increased to $24.8 million from $16.2 million a year ago. Reported net income of $4.9 million compared to a net loss of $11.0 million.
- The medical claims expense ratio was 77.0%, compared to 73.0% in Q1 FY21, due to the inclusion of Direct Contracting Entity (DCE) members who we initially expect to have higher medical costs, and, to a lesser extent, by higher elective procedure utilization and costs related to COVID-19.
- Cano Health had $319 million of cash, cash equivalents, and restricted cash at the end of the quarter.
- FY21 Guidance: Cano increased membership guidance to approximately 215,000, up from 205,000 - 210,000 previously.
- It expects revenue of about $1.6 billion, better than consensus and guidance of $1.5 billion. It forecasts adjusted EBITDA of $115 million versus $110 million previously and reaffirms to open 15 to 20 de novo medical centers in 2021
- FY22 Guidance: Cano sees sales of $2.5 billion - $2.6 billion (consensus $2.15 billion), an increase from the prior guidance of approximately $2.23 billion.
- It expects adjusted EBITDA of $165 million - $170 million, up from the prior outlook of $150 million.
- Price Action: CANO shares are up 12.10% at $11.95 during the premarket session on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: EarningsLong IdeasNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefsmedicare
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
